New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
16:15 EDTOMEROmeros reports Q2 EPS (53c) with items, consensus (52c)
Reports Q2 revenue $45,000, consensus $130,000. Q2 results included $2.5M, or 7c per share of non-cash expenses. The decrease in revenue, year over year, was due to a reduction of activity on NIH grant projects, which resulted in lower revenue being recognized.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
07:58 EDTOMEROmeros weakness creates buying opportunity, says Wedbush
After Omeros' stock sank about 23% since June 22, Wedbush notes that on June 25 an article recommended selling Omeros' stock. The firm says that the article based its conclusion on financial parameters suited to a mature, profitable company, rather than one which just launched its first drug, as is the case with Omeros. Wedbush adds that if the selloff in the stock was caused by the article, it recommends buying the shares. It believes that Omeros' fundamentals haven't changed, while the company has potentially significant catalysts this year. Wedbush keeps an Outperform rating on Omeros.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use